Anbogen Therapeutics, a Taipei, Taiwan-based clinical-stage biotechnology company, raised $12.5M in Series A funding.
The round was led by China Development Industrial Bank (CDIB), with participation from Taian Venture Capital, Maxpro and the National Development Fund.
The company intends to use the funds to accelerate the development its two main drug candidates, ABT-101 and ABT-301.
Led by CEO Dr. Tsu-An Hsu, and General Manager Joe Hsueh, Anbogen is a clinical-stage biotechnology company dedicated to developing precision anti-cancer drugs that hold the/promise of curing cancers and/or improving the lives of cancer patients worldwide. It aligns with national policies and addresses medical needs.
ABT-101, a HER2-targeting tyrosine kinase inhibitor (TKI), has exhibited substantial potency and safety during its pre-clinical and phase 1b clinical trial. During the pre-clinical study, ABT-101 demonstrated superior selectivity against HER2 exon20 insertion mutation.
Additionally, Anbogen is actively progressing ABT-301, a novel small molecule drug that potentiates efficacy of immune checkpoint inhibitors (ICIs). Having completed its phase 1 trial, ABT-301 exhibited superior safety and pharmacokinetic profiles compared to other marketed drugs with similar mechanism of action. Repeated animal studies reveal a surprising synergistic effect when ABT-301 is used in combination with immune ICIs (anti-PD1/anti-PD-L1) in animal models including colorectal cancer of microsatellite stable (MSS). ABT-301 can modulate the tumor microenvironment, increase the number of killer T cells in peripheral blood and infiltrating the tumor, enabling ICIs to overcome the limitations of “cold” tumors and produce immunotherapeutic effects.
Commenting on the news, Tsu-An Hsu said: “Signs of safety and clinical benefits have been observed in non-small cell lung cancer patients, including sustained tumor suppression in patients who previously developed resistance to Enhertu treatment.”
FinSMEs
01/02/2024